Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Aethlon Hemopurifier

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 18 years of age and older.~2. Positive test for HCV infection (any genotype).~3. End-stage-renal disease (ESRD) requiring dialysis - already established on HD.~4. The arteriovenous fistula, graft or central venous catheter must have been functioning adequately for at least 1 month before entry into study showing no signs of infection or blockage.~5. Have recovered from the toxicity of any prior systemic therapy.~6. Ability to tolerate blood volume losses of up to 150 ml per week, i.e. 50 ml each.~7. Stable clinical condition, including stable hemoglobin which has not fluctuated more than 1.5 -2.0 gm/dl within 28 days prior to enrollment into study.~8. Must have the following minimum hematologic, biochemical, and serologic criteria documented within 28 days prior to enrollment into study:~   1. Hemoglobin values of ≥ 9.5 gm/dL for males and females~  2. Platelet count \> 100,000/mm3~  3. Bilirubin \< 4 mg/dL~  4. Albumin stable and not less than 3.5 g/dl.~9. Women of child-bearing potential must be practicing barrier or oral contraception for the duration of the study or documented as surgically sterile or one year post-menopausal.~10. If female, be non-nursing, non-pregnant and have a negative serum or urine pregnancy test within two weeks of starting study.~11. The subject must be informed of the investigational nature of this study and written informed consent obtained prior to enrollment in this study.~12. The subject must be able to comprehend the study description and its nature as only a feasibility study.~Exclusion Criteria:~1. Administration of Pegasys-ribavirin or ANY anti-viral drug therapy within 90 days prior to enrollment into study.~2. Administration of any other investigational drugs within 90 days prior to enrollment into study.~3. Clinically significant infection, other than HCV, defined as any acute or chronic viral, bacterial, or fungal infection, which requires specific therapy (Anti-infectious therapy must have been completed at least 14-days before entry into study) in order to make entry into the study possible.~4. Patient infected with human immunodeficiency virus or has AIDS.~5. A history of hypotensive episodes during dialysis which lead to early termination of the treatment in the 2 treatments prior to the start of study treatments.~6. Patients who have received an ACE (angiotensin converting enzyme) inhibitor within the last 24 hours should not be treated. Patients receiving an ACE inhibitor may experience an anaphylactoid-like reaction, including hypotension associated with flushing, dyspnea, and bradycardia. Such reactions, if left untreated, may be life-threatening. The administration of ACE inhibitors also has been associated with the occurrence of tachycardia. Risk of an anaphylactoid-like reaction or tachycardia may be minimized by the temporary cessation of the administration of ACE inhibitors for 6 days or longer before initiating the treatment protocol.~7. Any known pre-existing medical condition that could interfere with the subject's participation in the entire protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly-controlled diabetes mellitus as indicated by an Hb-A1c \> 8% within the two weeks prior to protocol initiation, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe interdialytic hypotension, or significant arrhythmia).~8. Subjects with ECG showing clinically significant abnormalities.~9. Dementia or other cognitively-limiting disease processes which would make it difficult for the patient to articulate their clinical status.~10. Prior blood transfusion for any reason within 3 months prior to enrollment into study.~11. Recent history of bleeding or bleeding disorders that would likely require the restriction in use of heparin during study treatments.~12. Active immunologically mediated disease (e.g., inflammatory bowel disease \[Crohn's disease, ulcerative colitis\], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis).~13. Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immunoregulatory medications.~14. Substance abuse, such as alcohol (\~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months. Subjects receiving methadone within the past year are also excluded.)~15. Any cancer requiring systemic chemotherapy or radiotherapy.~16. Any other condition that, in the opinion of the Principal Investigators, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemopurifier (Type: EXPERIMENTAL): Affinity plasmapheresis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues